Efficacy and tolerance of LV5FU2-carboplatin chemotherapy in patients with advanced pancreatic ductal adenocarcinoma after failure of standard regimens
暂无分享,去创建一个
V. Rebours | P. Lévy | O. Hentic | P. Hammel | L. de Mestier | M. Dioguardi Burgio | N. Muller | T. Chaigneau | Lina Aguilera Munoz | L. Laurent | Marie-Pauline Gagaille | Caroline Oger | Clémence Gourdeau
[1] P. Turano,et al. Comparative NMR metabolomics of the responses of A2780 human ovarian cancer cells to clinically established Pt-based drugs. , 2022, Dalton transactions.
[2] Jin Ho Choi,et al. A real-world analysis of nanoliposomal-irinotecan with 5-fluorouracil and folinic acid as third- or later-line therapy in patients with metastatic pancreatic adenocarcinoma , 2022, Therapeutic advances in medical oncology.
[3] Eun Mi Lee,et al. The clinical outcomes of second-line chemotherapy in patients with advanced pancreatic cancer: a retrospective study , 2021, Yeungnam University journal of medicine.
[4] R. Greil,et al. Non-pegylated Liposomal Doxorubicin as Palliative Chemotherapy in pre-Treated Advanced Pancreatic Cancer: A Retrospective Analysis of Twenty-Eight Patients , 2021, Technology in cancer research & treatment.
[5] E. Brun,et al. Second-line palliative chemotherapy, survival, and prognostic factors in patients with advanced pancreatic cancer , 2021, Acta oncologica.
[6] N. Sasahira,et al. Treatment outcomes of erlotinib plus gemcitabine as late-line chemotherapy in unresectable pancreatic cancer. , 2021, Japanese journal of clinical oncology.
[7] C. Nielson,et al. Relative Dose Intensity of Chemotherapy and Survival in Patients with Advanced Stage Solid Tumor Cancer: A Systematic Review and Meta‐Analysis , 2021, The oncologist.
[8] K. Kiura,et al. Dramatic Response to Carboplatin Plus Paclitaxel in Pancreatic Mucinous Cystadenocarcinoma with Liver Metastasis , 2021, Internal medicine.
[9] L. Matrisian,et al. Estimated Projection of US Cancer Incidence and Death to 2040 , 2021, JAMA network open.
[10] A. Reyniès,et al. A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] X. Lao,et al. Worldwide Burden of, Risk Factors for, and Trends in Pancreatic Cancer. , 2020, Gastroenterology.
[12] Hongping Chen,et al. Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment , 2020, Journal of Neurology.
[13] Versione,et al. Common Terminology Criteria for Adverse Events , 2020, Definitions.
[14] R. Hruban,et al. Recent trends in the incidence and survival of Stage 1A Pancreatic Cancer: A Surveillance, Epidemiology, and End Results analysis. , 2020, Journal of the National Cancer Institute.
[15] C. Tournigand,et al. Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial. , 2019, European journal of cancer.
[16] H. Lee,et al. Analysis of Clinical Predictive Factors Affecting the Outcome of Second-Line Chemotherapy for Gemcitabine-Refractory Advanced Pancreatic Cancer , 2019, Gut and liver.
[17] T. Conroy,et al. Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). , 2018, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[18] Yvonne E. Moussa,et al. The side effects of platinum-based chemotherapy drugs: a review for chemists. , 2018, Dalton transactions.
[19] Yves Pommier,et al. A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress , 2017, Nature Medicine.
[20] I. Ilic,et al. Epidemiology of pancreatic cancer , 2016, World journal of gastroenterology.
[21] S. Gill,et al. PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] B. Dörken,et al. Second-Line Treatment in Pancreatic Cancer Patients: Who Profits?—Results From the CONKO Study Group , 2016, Pancreas.
[23] Yan-Shen Shan,et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial , 2016, The Lancet.
[24] A. Biankin,et al. Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials. , 2015, Critical reviews in oncology/hematology.
[25] J. Kench,et al. Whole genomes redefine the mutational landscape of pancreatic cancer , 2015, Nature.
[26] A. Ko,et al. Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options? , 2014, World journal of gastroenterology.
[27] David Goldstein,et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.
[28] H. Sorbye,et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[29] D. Brizel,et al. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .
[30] B. Dörken,et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. , 2011, European journal of cancer.
[31] Pierre Michel,et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.
[32] A. V. Pavlovsky,et al. A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. , 2009, European journal of cancer.
[33] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[34] R. Eeles,et al. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] H. Gogas,et al. Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.